Curaleaf Holdings Inc (CURA.TO) Buy, Sell or…

Home

Daily Stock Opinions and Ratings

Curaleaf Holdings Inc (CURA.TO)

13.45

+0.46 (3.54%)

as of Aug 28, 2026, 8:00:00 pm Market Open.

119 watching

Investor Insights

Aug 31, 2026, 12:00 am

This summary was created by AI, based on 5 opinions in the last 12 months.

Curaleaf Holdings Inc (CURA) has garnered attention due to the potential rescheduling of cannabis, which could significantly reduce tax burdens for companies in the sector. Although excitement surged last year, leading to volatile spikes in stock prices, experts emphasize the unpredictability surrounding legislative changes in cannabis laws. Competitors like Trulieve (TRUL) are mentioned as being in a similar position, showcasing the sector's dual nature of potential growth alongside inherent risks tied to political developments. Despite challenges related to tax restrictions on business expenses, the overall sentiment is cautiously optimistic, as the industry's financials have improved, presenting opportunities for undervalued stocks in the cannabis market. However, investors are advised to maintain small positions until cash flow becomes more stable.

Consensus

Cautious

Valuation

Undervalued

Similar

Trulieve,TRUL

Unspecified

This was dragged down with the Cannabis sector and delays in U.S. Cannabis legislation. Has good governance and should be one of the winners in this space. Long term growth is good but not so much short term. Chairman and founder owns $800 million in stock. He owns personally but not for clients.

BUY

US multi-state operator (MSO). Most stocks peaked a year ago, and have been in decline since. Continues to grow. Regulatory and structural issues have caused selling pressure. At some point, valuations will catch up. Leader, biggest MSO. The Cadillac.

PAST TOP PICK

(A Top Pick Jan 07/21, Down 40%) Still has confidence in the name. An emerging growth sector with ups and downs. Company strategy plus industry dynamics will make it a long-term winner. Victim of sentiment and legislative delays. Heightened competition. Still buying.

BUY

One of the leaders. Revenue and EBITDA numbers in the sector have been significant; valuations are attractive, and they're growing. Strategy of both building and buying. After tax loss selling, and into next year, more investors should be looking at it. Catalyst from US legislators would be icing on the cake.

BUY

Emerging growth industry that will be very big in time. Will be one of the dominant players. Likes the pullback, along with the valuation. Whole sector has pulled back on sentiment, legislative delays, heightened competition in Florida. When fundamentals improve, but the stock price goes the other way, you buy.

BUY

Got ahead of itself last year. Continues to buy. A likely winner in the new industry. Not currently profitable, due to old laws on the books about expense deductions. This will change, though probably not this year. Regulatory changes will reduce their cost of capital. Upswings will outweigh downswings over time.

PAST TOP PICK

(A Top Pick Nov 05/20, Up 9%) He bought this in summer 2020 at $10 then shot up to $21 last January because Biden became U.S. President. Curaleaf operates entirely in America. He still believes weed will be legalized in the U.S., so believes in Curaleaf. Exposure to the U.S. market is crucial. Curaleaf is vertically integrated, so checks that box, on top of great governance that owns a lot of shares. Curaleaf is well-positioned and an early mover. Now is a great entry point.

TOP PICK

Early in the story was a sceptic. Initiated a position last summer. Biggest company in cannabis by revenue. There is an e-report available. Vertically integrated with good geographic footprint. Good organic growth, with more licenses to open more. Great management team. Pullback is buyable. (Analysts’ price target is $28.06)

DON'T BUY

He does not do a lot of Cannabis investing. It is a leading US MSO. The industry is still very early days. Once we have more interstate commerce allowed amongst the names you will see them firm quite a bit. His favourite is Air Wellness.

BUY

Results reported yesterday were good. Elephant in the room is is what happens with US cannabis regulations. Impediment to greater profitability is they can't deal with mainstream banks, so cost of capital is higher. Plus, illegal federally, so pay astronomical tax rates. Regulations will eventually change. Best of breed.

BUY

Canadian-listed, international company. One of the leaders in NA and Europe. Lots of opportunity in the US, where the tide is toward full legalization.

BUY

A bifurcated industry, with those financially sound vs. the other ones. Pleased with how they're growing their business. Large addressable market in Europe. Not profitable, but revenue is growing quickly. Vertically integrated. 100+ dispensaries downstream. Likes geographic footprint. Going to be a long-term leader in what will be a huge industry.

BUY

Until this week, Curaleaf was the leader in this space. Yesterday, Trulieve Cannabis and Harvest merged to bump Curaleaf out of that spot in terms of EBITDA. That said, Curaleaf has done a great job executing in many U.S. states. They cultivate, producer and sell cannabis in dispensaries. Their profit margin is strong. This will be one of the fastest-growing sectors in the US and the world in the coming decade. The company has just bought into Europe and expanding their footprint to become a global producer. Shares have certainly pulled back. But it issued strong earnings today but markets are selling off today, so the stock price isn't up as much as it should be. He's happy to own it.

TOP PICK

His pick in cannabis (the complete opposite to Organigram). They're a Canadian company but they operate entirely in the U.S., and (after a recent $300 million purchase) five western European countries. In terms of cannabis legalization, Europe is roughly where the U.S. was three years ago. He alsolikes that they're vertically integrated with 23 cultivation sites, 24 processing ones, and 106 dispensaries with licenses to add 30 across 23 American states. He likes that they're leveraging their roots in medical MJ, branching into the bigger recreational market. They rise above other cannabis companies by offering good governance, sound strategy and executive ownership of shares. Checks all the boxes. (Analysts’ price target is $28.02)

BUY ON WEAKNESS

Has pulled back recently. The whole marijuana sector who has had a huge move is taking a breather. Bought around $10. The pull-back is buyable. The geographic foot print, strategy and vertical integration is positive. They own growers, intermediate processors, and has good downstream footprint. The regulatory and social license backdrop is good with Biden and the democrats. Addressable market is huge.

Showing 16 to 30 of 35 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Jim Lebenthal

Cerity Partners

Bill Baruch, Founder, Blue Line Capital

Blue Line Capital

Brianne Gardner

Raymond James

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Curaleaf Holdings Inc (CURA.TO)